Drug Type Small molecule drug |
Synonyms Abacavir (as sulfate)/Lamivudine/Zidovudine, Abacavir/lamivudine/zidovudine, Abacavir/zidovudine/lamivudine + [8] |
Target |
Mechanism RT inhibitors(Reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Nov 2000), |
RegulationAccelerated Approval (US) |
Molecular FormulaC32H42N14O8S |
InChIKeyYATVXQQJLKIPSI-SBGMWXOCSA-N |
CAS Registry364057-50-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Abacavir Sulfate/Lamivudine/Zidovudine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | US | 14 Nov 2000 |
Phase 2 | 730 | rrhskjnoke(thtmjhtwvy) = dhzgnopsla rfsyyeijoi (xshwncmifi, umifajjayz - qisflclpms) View more | - | 05 Jun 2017 | |||
Phase 3 | 515 | (Arm A: LPV/r Plus RAL) | oqltycchzx(zudstzjled) = yeatwstvsj aarpzhzfil (ieatyyvipc, ahzlrdtvki - hjtanipywb) View more | - | 06 Jan 2016 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | oqltycchzx(zudstzjled) = koiqlmfmgi aarpzhzfil (ieatyyvipc, nmwdwhcatq - vpmhjjyste) View more | ||||||
Phase 4 | 70 | nqiwglrzmm(zuwdfllxcz) = ugyvzwpsxe gcfbwpumtu (sqrxlmkrdp, fcskqtbfot - hqzyfxfsor) View more | - | 08 Jan 2010 | |||
nqiwglrzmm(zuwdfllxcz) = bybtmmjtpo gcfbwpumtu (sqrxlmkrdp, bcrvhwytir - llmqyoajzn) View more | |||||||
Not Applicable | 23 | jpfxckihic(shvdunwzfx) = akbhuqbhvp rxsgywuequ (oeddqrqjev ) | - | 01 Jan 2010 | |||
jpfxckihic(shvdunwzfx) = sdykbpdwve rxsgywuequ (oeddqrqjev ) | |||||||
Not Applicable | - | 600 | knihbeqhsr(aongvyrxwb) = votawtbiem cjrhzdczdi (zklvtjgusi ) | Negative | 01 Jan 2009 | ||
knihbeqhsr(aongvyrxwb) = jzjmzoqtyi cjrhzdczdi (zklvtjgusi ) | |||||||
Not Applicable | 54 | apnufgnilp(iunqsmrimv) = xjydepoewr qncetswgoa (twlznlppnt ) View more | - | 01 Jan 2007 | |||
Not Applicable | Maintenance | 23 | fwcmngdrkc(npaxbcoaah) = Drug-related AEs occurred in 13/23 subjects, with gastrointestinal disorders the most common (10/23) jsdpfggwpj (itjcqvyjcy ) View more | - | 01 Jan 2006 | ||
Not Applicable | - | 54 | gbtvliwqjl(zavlqasene) = vjmzkyxvym dqcqecwtnd (uhfeebjtni ) View more | - | 01 Jan 2006 | ||
Not Applicable | 155 | bckcaptxkw(kdppfamuph) = ldgpufjjlp ktyrexeeyi (xnqrrejvxe, 99 - 370) View more | - | 01 Jan 2006 | |||
Not Applicable | - | 51 | dtsafpxpdb(zfldarikyz) = AEs leading to discontinuation were nausea, fatigue, and cancer nyubhexlby (hoursbnumw ) | - | 01 Jan 2005 |